madman
Super Moderator
* Male sexual symptoms are biologically heterogeneous and clinically nonspecific. Erectile dysfunction, reduced sexual desire, impaired spontaneous erections, and broader androgen-deficiency symptom clusters may arise from vascular, psychogenic, relational, neurological, metabolic, endocrine, or mixed mechanisms.
* In most men with erectile dysfunction, the highest-value initial laboratory panel consists of fasting glucose and/or hemoglobin A1c (HbA1c), a lipid profile, and early-morning fasting testosterone, provided recent results are unavailable.
* Low or borderline testosterone should be confirmed on a second independent early-morning fasting sample before biochemical classification, with attention to assay performance and to SHBG with calculated free testosterone when indicated. Prolactin testing is reserved for selected endocrine phenotypes and must account for medication use, macroprolactin, and the hook effect. Thyroid tests and estradiol should be phenotype driven rather than routine.
Fig. 1. Practical laboratory algorithm for men presenting with erectile dysfunction and/or reduced sexual desire.
4. Core initial testing in men with erectile dysfunction
4.1. Glycemic biomarkers
4.2. Lipid biomarkers and cardiovascular context
5. Testosterone, sex hormone-binding globulin (SHBG), calculated free testosterone, and gonadotropins
5.1. Preanalytical control
5.2. Action limits rather than rigid universal cutoffs
5.3. Assay performance and interlaboratory variation
5.4. SHBG and calculated free testosterone
5.5. Free androgen index in men
5.6. Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) as second-tier classifiers
6. Prolactin, macroprolactin, and the hook effect
6.1. Indication and repeat confirmation
6.2. Macroprolactin
6.3. Hook effect
6.4. Sexual symptoms and treatment relevance
7. Thyroid function tests in selective endocrine extension
8. Estradiol: narrow indications, major assay constraints
11. Conclusions
Laboratory testing in erectile dysfunction, reduced sexual desire, and suspected hypogonadism should not be organized as a uniform endocrine panel. It is better understood as a tiered decision strategy built around a small routine core and a second tier of phenotype-driven endocrine biomarkers.
For most men presenting with erectile dysfunction, fasting glucose and/or hemoglobin A1c (HbA1c), a lipid profile, and early-morning fasting testosterone provide the highest-value initial panel. Testosterone remains central but requires preanalytical discipline, confirmation on two independent early-morning fasting samples when low or borderline, attention to assay performance, and integration of SHBG with calculated free testosterone when indicated. Prolactin is highly informative in selected phenotypes provided medication effects, macroprolactin, secondary causes, and the hook effect are addressed. Thyroid biomarkers can meaningfully reframe selected cases when systemic, endocrine disease or assay interference is plausible. Estradiol has the narrowest role and should be ordered selectively and measured with appropriate low-range analytical performance [1–11,14–18,20–24,26].
Across all sections, the same principle applies: a biomarker is useful only when it is clinically indicated, analytically trustworthy, and capable of changing management. When those conditions are ignored, testing drifts toward noise. When they are respected, laboratory medicine becomes an efficient tool for sexual-symptom phenotyping, detection of systemic disease, and better-aligned clinical decision-making [12].
The algorithm distinguishes core high-value tests from phenotype-driven endocrine extension. In most men, the initial panel includes fasting glucose and/or hemoglobin A1c (HbA1c), a lipid profile, and early-morning fasting testosterone if recent relevant results are unavailable. Low or borderline testosterone requires confirmation on a second independent early-morning fasting sample. Sex hormone-binding globulin (SHBG) with calculated free testosterone should then be interpreted when total testosterone is borderline or low, or when altered binding-protein physiology creates interpretive uncertainty, before etiologic classification with luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Prolactin is reserved for men with low sexual desire, suspected secondary hypogonadism, pituitary symptoms, or endocrine discordance; persistent elevation requires consideration of medication effects, secondary causes, macroprolactin, and the hook effect when imaging and chemistry disagree. Thyroid testing and estradiol are used selectively according to phenotype and analytical suitability [1–11,14–18,20–24,26].
* In most men with erectile dysfunction, the highest-value initial laboratory panel consists of fasting glucose and/or hemoglobin A1c (HbA1c), a lipid profile, and early-morning fasting testosterone, provided recent results are unavailable.
* Low or borderline testosterone should be confirmed on a second independent early-morning fasting sample before biochemical classification, with attention to assay performance and to SHBG with calculated free testosterone when indicated. Prolactin testing is reserved for selected endocrine phenotypes and must account for medication use, macroprolactin, and the hook effect. Thyroid tests and estradiol should be phenotype driven rather than routine.
Fig. 1. Practical laboratory algorithm for men presenting with erectile dysfunction and/or reduced sexual desire.
4. Core initial testing in men with erectile dysfunction
4.1. Glycemic biomarkers
4.2. Lipid biomarkers and cardiovascular context
5. Testosterone, sex hormone-binding globulin (SHBG), calculated free testosterone, and gonadotropins
5.1. Preanalytical control
5.2. Action limits rather than rigid universal cutoffs
5.3. Assay performance and interlaboratory variation
5.4. SHBG and calculated free testosterone
5.5. Free androgen index in men
5.6. Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) as second-tier classifiers
6. Prolactin, macroprolactin, and the hook effect
6.1. Indication and repeat confirmation
6.2. Macroprolactin
6.3. Hook effect
6.4. Sexual symptoms and treatment relevance
7. Thyroid function tests in selective endocrine extension
8. Estradiol: narrow indications, major assay constraints
11. Conclusions
Laboratory testing in erectile dysfunction, reduced sexual desire, and suspected hypogonadism should not be organized as a uniform endocrine panel. It is better understood as a tiered decision strategy built around a small routine core and a second tier of phenotype-driven endocrine biomarkers.
For most men presenting with erectile dysfunction, fasting glucose and/or hemoglobin A1c (HbA1c), a lipid profile, and early-morning fasting testosterone provide the highest-value initial panel. Testosterone remains central but requires preanalytical discipline, confirmation on two independent early-morning fasting samples when low or borderline, attention to assay performance, and integration of SHBG with calculated free testosterone when indicated. Prolactin is highly informative in selected phenotypes provided medication effects, macroprolactin, secondary causes, and the hook effect are addressed. Thyroid biomarkers can meaningfully reframe selected cases when systemic, endocrine disease or assay interference is plausible. Estradiol has the narrowest role and should be ordered selectively and measured with appropriate low-range analytical performance [1–11,14–18,20–24,26].
Across all sections, the same principle applies: a biomarker is useful only when it is clinically indicated, analytically trustworthy, and capable of changing management. When those conditions are ignored, testing drifts toward noise. When they are respected, laboratory medicine becomes an efficient tool for sexual-symptom phenotyping, detection of systemic disease, and better-aligned clinical decision-making [12].
The algorithm distinguishes core high-value tests from phenotype-driven endocrine extension. In most men, the initial panel includes fasting glucose and/or hemoglobin A1c (HbA1c), a lipid profile, and early-morning fasting testosterone if recent relevant results are unavailable. Low or borderline testosterone requires confirmation on a second independent early-morning fasting sample. Sex hormone-binding globulin (SHBG) with calculated free testosterone should then be interpreted when total testosterone is borderline or low, or when altered binding-protein physiology creates interpretive uncertainty, before etiologic classification with luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Prolactin is reserved for men with low sexual desire, suspected secondary hypogonadism, pituitary symptoms, or endocrine discordance; persistent elevation requires consideration of medication effects, secondary causes, macroprolactin, and the hook effect when imaging and chemistry disagree. Thyroid testing and estradiol are used selectively according to phenotype and analytical suitability [1–11,14–18,20–24,26].
